| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.230.712 |
| Chemical and physical data | |
| Formula | C31H43NO10 |
| Molar mass | 589.682 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Norbuprenorphine-3-glucuronide (N3G) is a majoractive metabolite of theopioid modulatorbuprenorphine.[1] It hasaffinity for theκ-opioid receptor (Ki = 300 nM) and thenociceptin receptor (Ki = 18 μM), but not for theμ- orδ-opioid receptors.[1] Whether N3G acts as anagonist orantagonist of each of the former two respective sites has yet to be determined.[2] In animals, N3G has been found to producesedation, decreasedlocomotion, and a small amount ofantinociception, properties which are consistent with the effects of κ-opioid receptor agonists.[1] In addition, N3G has been found to reducetidal volume but notrespiratory rate.[1] Unlikenorbuprenorphine, but similarly to buprenorphine andbuprenorphine-3-glucuronide, N3G is not asubstrate forP-glycoprotein.[2] However, due to its highlyhydrophilic nature, N3G nonetheless passes theblood-brain-barrier in only very small amounts.[2]